Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendMost-Upgraded StocksMost-UpgradedNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $263.90 -0.12 (-0.05%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$264.50 +0.60 (+0.23%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbbVie Stock (NYSE:ABBV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbbVie alerts:Sign Up Key Stats Today's Range$262.44▼$266.3450-Day Range$243.64▼$265.6352-Week Range$190.75▼$267.47Volume8.16 million shsAverage Volume3.92 million shsMarket Capitalization$466.26 billionP/E Ratio74.55Dividend Yield2.62%Price Target$276.64Consensus RatingModerate Buy Company Overview AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals. AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions. Its neuroscience products include Botox Therapeutic, Vraylar, Ubrelvy and Qulipta, while its aesthetics business markets Botox Cosmetic and the Juvéderm collection of dermal fillers. AbbVie also develops and markets treatments in oncology, including Imbruvica, Venclexta and Epkinly, as well as products in eye care and women’s health. The company sells its products in the United States and international markets through commercial operations, research activities and partnerships spanning numerous countries. AbbVie is headquartered in North Chicago, Illinois. Robert A. Michael has served as the company’s chief executive officer since 2020, following a leadership succession from longtime CEO Richard A. Gonzalez.AI Generated. May Contain Errors. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreABBV MarketRank™: AbbVie scored higher than 78% of companies evaluated by MarketBeat, and ranked 133rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 18 buy ratings, 5 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbbVie has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth14.95% Earnings GrowthEarnings for AbbVie are expected to grow by 14.95% in the coming year, from $14.05 to $16.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 74.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 74.55, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.22.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.Read more about AbbVie's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.11% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in AbbVie has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbVie pays a meaningful dividend of 2.62%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 42.85% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. News and Social Media3.8 / 5News Sentiment1.00 News SentimentAbbVie has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 52 news articles for AbbVie this week, compared to 10 articles on an average week.Search InterestOnly 74 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows95 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 70% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.Percentage Held by Insiders0.06% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Stock News HeadlinesAbbVie (ABBV) Unveiled New VRAYLAR Data In Real World And Pediatric Care4 hours ago | finance.yahoo.comAbbVie Presents New Real-World Data Supporting Effectiveness of VRAYLAR (Cariprazine) At Psych Congress 2026September 18 at 11:20 PM | marketscreener.comMYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 19 at 1:00 AM | Profits Run (Ad)AbbVie’s Dividend Growth Remains Solid Despite a Moderate YieldSeptember 18 at 2:31 PM | insidermonkey.comAbbVie Reports Real-World Data For VRAYLAR In Depressive DisorderSeptember 18 at 1:19 PM | rttnews.comAbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society MeetingSeptember 18 at 1:19 PM | marketscreener.comMModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (ABBV)Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.September 6, 2026 | marketbeat.comInsider Selling: AbbVie (NYSE:ABBV) EVP Sells $8,177,500.00 in StockAugust 20, 2026 | insidertrades.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $228.55 at the beginning of the year. Since then, ABBV shares have increased by 15.5% and is now trading at $263.9010. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Friday, July, 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The company's revenue for the quarter was up 10.2% on a year-over-year basis. Read the conference call transcript. Does AbbVie have any subsidiaries? AbbVie subsidiaries include Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others. Who are AbbVie's major shareholders? AbbVie's top institutional investors include BlackRock Inc. (8.46%), Bank of America Corp DE (1.20%), Corient Private Wealth LP (1.11%) and Corient Private Wealth LP (1.11%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Perry C Siatis, Scott T Reents, Kevin K Buckbee and David Ryan Purdue. View institutional ownership trends. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC). Company Calendar Record date for 8/14 Dividend7/15/2026Ex-Dividend for 8/14 Dividend7/15/2026Last Earnings7/31/2026Dividend Payable8/14/2026Today9/19/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Next Earnings (Estimated)10/30/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ABBV's financial health is in the Green zone, according to TradeSmith. ABBV has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees57,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$276.64 High Price Target$315.00 Low Price Target$223.00 Potential Upside/Downside+4.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$3.54 Trailing P/E Ratio74.55 Forward P/E Ratio18.78 P/E Growth1.19Net Income$4.23 billion Net Margins9.80% Pretax Margin13.51% Return on Equity-422.07% Return on Assets14.34% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69 Sales & Book Value Annual Sales$61.16 billion Price / Sales7.62 Cash Flow$15.14 per share Price / Cash Flow17.43 Book Value($1.83) per share Price / Book-144.21Miscellaneous Outstanding Shares1,766,790,000Free Float1,765,733,000Market Cap$466.26 billion OptionableOptionable Beta0.29 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:ABBV) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
